Sarepta Therapeutics, Inc.

Organisation

215 First Street, Cambridge, MA, United States, 02142

Headquarters

Employees

Health Technology

Industry

Douglas Ingram

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Price

Target

Sarepta Therapeutics, Inc. (SRPT) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Sarepta Therapeutics, Inc. (SRPT) share price will touch around $20.61 in next 12-months.

Currently 29 wall-street analysts regularly analyze the financials of Sarepta Therapeutics, Inc. on a frequent basis to provide recommendations along with target share price. 29 analysts offering 12-month price forecasts for Sarepta Therapeutics, Inc. (SRPT) have a share price target of $20.61. This median of share price forecast represents a 20.1% upside from the latest price of $17.16 as on 19.03.26.

Sarepta Therapeutics, Inc. (SRPT) Share Price Forecast

Home

US Stocks

Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc. Stock Forecast

Sarepta Therapeutics, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Sarepta Therapeutics, Inc. (SRPT): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Sarepta Therapeutics, Inc.'s share price and its median forecast price. As on 19.03.26, the difference is -4.31%

Sarepta Therapeutics, Inc. Forecast and Target Price

Sarepta Therapeutics, Inc. (SRPT) Share Price Forecast

Sarepta Therapeutics, Inc. (SRPT) Price vs Consensus Price Target

Sarepta Therapeutics, Inc. (SRPT) Share Price Forecast v/s Share Price Today

Sarepta Therapeutics, Inc. (SRPT): Difference between Current Price & Median Forecasted Price

Sarepta Therapeutics, Inc. (SRPT) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price